Exploring alternative neoadjuvant chemotherapy options for the KEYNOTE-522 regimen: Insights from real-world experience within HK’s public healthcare system
27 Jun 2025
byDr. Thomas Kwan-Hang Lau, Department of Clinical Oncology, Prince of Wales Hospital; Dr. Kang Li, Department of Clinical Oncology, Prince of Wales Hospital
Despite positive outcomes with the KEYNOTE-522 regimen for triple-negative breast cancer (TNBC), its implementation faces challenges due to resource constraints in Hong Kong’s public healthcare system. Consultant Dr Thomas Kwan-Hang Lau and Resident Dr Kang Li of the Department of Clinical Oncology at Prince of Wales Hospital (PWH) shared insights and a case series on the use of Q3W and Q1W chemotherapy for the KEYNOTE-522 regimen in PWH and explored alternative neoadjuvant chemotherapy options.
Exploring alternative neoadjuvant chemotherapy options for the KEYNOTE-522 regimen: Insights from real-world experience within HK’s public healthcare system
27 Jun 2025
